source
- J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trialJohnson & Johnson's recent $3 billion purchase of Halda Therapeutics added an oral prostate cancer candidate, JNJ-6143, to its pipeline. The drug targets a cancer-specific protein to trigger cell d…
- Health insurance premiums surge as CMS ramps up Medicaid fraud crackdownPremiums for health insurance are climbing sharply, putting pressure on both large and small employers. While many firms have absorbed the cost to stay competitive, smaller businesses are beginning…